Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Arrowhead stock soars on $825M Sarepta Therapeutics deal

admin by admin
November 26, 2024
in Stock
0
Arrowhead stock soars on $825M Sarepta Therapeutics deal
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

On Tuesday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares surged by 32% following the announcement of a comprehensive licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ:SRPT). The transaction, poised to close in early 2025, will see Arrowhead receiving an immediate $825 million, including a $500 million upfront payment and a $325 million equity investment at a 35% premium. Additionally, Arrowhead is set to receive $250 million over the next five years and could earn up to $10 billion in future milestone payments, along with royalties on product sales.

The partnership grants Sarepta access to Arrowhead’s Targeted RNAi Molecule (TRiM) platform to develop treatments for rare genetic diseases affecting muscles, the central nervous system, and lungs. Sarepta will also have the option to select up to six new targets for Arrowhead to explore in preclinical development.

Arrowhead’s President and CEO, Christopher Anzalone, Ph.D., highlighted the deal’s significance, stating it provides “a transformational amount of capital” and the potential for substantial non-dilutive funding. The agreement is expected to extend Arrowhead’s cash runway into 2028, supporting the launch of its investigational drug plozasiran and the advancement of its pipeline programs.

In conjunction with the agreement, Sarepta’s President and CEO, Doug Ingram, will join Arrowhead’s Board of Directors, bringing his extensive experience in advancing investigational medicines and launching commercial drugs.

Arrowhead is on track to receive an additional $300 million in near-term clinical trial enrollment-related payments within the next 12 months. The company is also eligible for development milestone payments ranging from $110 million to $410 million per program and sales milestone payments between $500 million and $700 million per program. Arrowhead will also earn tiered royalties on commercial sales.

The current clinical programs under the agreement include ARO-DUX4 for facioscapulohumeral muscular dystrophy type 1, ARO-DM1 for type 1 myotonic dystrophy, ARO-MMP7 for idiopathic pulmonary fibrosis, and ARO-ATXN2 for spinocerebellar ataxia 2. Preclinical programs ARO-HTT, ARO-ATXN1, and ARO-ATXN3 are expected to be ready for clinical trial applications in the coming years.

Arrowhead will discuss the details of this agreement during its fiscal year-end results conference call on Tuesday, November 26, 2024, at 4:30 p.m. ET. The closing of the transaction is contingent upon regulatory approvals and customary closing conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com

Previous Post

What Scott Bessent’s Treasury nomination could mean for the economy, tariffs

Next Post

Best Buy annual forecasts take a knock from weak electronics demand

admin

admin

Next Post
Best Buy annual forecasts take a knock from weak electronics demand

Best Buy annual forecasts take a knock from weak electronics demand

Trending News

Microsoft is shutting down Skype: how Zoom and Microsoft’s own Teams sounded its death knell

Microsoft is shutting down Skype: how Zoom and Microsoft’s own Teams sounded its death knell

March 1, 2025
T-Mobile falls 6% on lagging phone subscriber growth; analysts acknowledge market strength but say TMUS is overvalued

T-Mobile falls 6% on lagging phone subscriber growth; analysts acknowledge market strength but say TMUS is overvalued

April 25, 2025
UK’s Crown Estate clears offshore wind expansion to raise energy output

UK’s Crown Estate clears offshore wind expansion to raise energy output

May 9, 2025
Subscribe to Insightful Word


    Recent News

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    June 6, 2025
    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    June 6, 2025
    Asian stocks end mixed: Hang Seng snaps winning streak, Nikkei jumps 0.5%

    Asian stocks end mixed: Hang Seng snaps winning streak, Nikkei jumps 0.5%

    June 6, 2025
    Starlink reportedly secures key licence in India, moves closer to launching services

    Starlink reportedly secures key licence in India, moves closer to launching services

    June 6, 2025

    Recent News

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    June 6, 2025
    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    June 6, 2025

    Latest News

    • China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll
    • FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more
    • Asian stocks end mixed: Hang Seng snaps winning streak, Nikkei jumps 0.5%

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.